Tanya M Laidlaw Selected Research

Rhinosinusitis

12/2023	Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.
10/2023	Increased epithelial mTORC1 activity in chronic rhinosinusitis with nasal polyps.
1/2022	Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
1/2022	Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
1/2022	Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
1/2021	The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.
1/2021	Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
1/2020	Biologics in chronic rhinosinusitis with nasal polyposis.
1/2020	Phenotypes of Chronic Rhinosinusitis.
11/2019	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tanya M Laidlaw Research Topics

Disease

40	Asthma (Bronchial Asthma) 01/2024 - 07/2012
25	Nasal Polyps (Nasal Polyp) 05/2024 - 04/2012
21	Inflammation (Inflammations) 05/2024 - 01/2010
13	Rhinosinusitis 12/2023 - 03/2014
11	Hypersensitivity (Allergy) 02/2024 - 09/2008
9	Eosinophilia 01/2024 - 10/2013
5	Polyps 10/2023 - 10/2015
3	Anosmia 01/2024 - 01/2022
3	Respiratory Hypersensitivity 12/2023 - 07/2012
3	Drug-Related Side Effects and Adverse Reactions 11/2023 - 01/2021
3	Rhinorrhea 09/2018 - 03/2014
3	Pneumonia (Pneumonitis) 10/2013 - 01/2010
2	Pain (Aches) 02/2024 - 01/2021
2	Chronic Cough 05/2022 - 12/2021
2	Cough 05/2022 - 12/2021
2	Aspirin-Induced Asthma 01/2020 - 01/2019
2	Bronchial Spasm 09/2018 - 11/2016
2	Respiratory Sounds (Crackle) 09/2018 - 03/2014
2	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 10/2015 - 07/2012
2	Vascular Remodeling 07/2012 - 01/2010
1	Neoplasms (Cancer) 04/2024
1	Persistent Infection 04/2024
1	Type 2 Diabetes Mellitus (MODY) 12/2023
1	Obesity 12/2023
1	Drug Hypersensitivity (Drug Allergy) 11/2023
1	Postoperative Pain 01/2023
1	Otitis Media with Effusion 01/2023
1	Sinusitis 01/2023
1	Arthralgia (Joint Pain) 01/2022
1	Chronic Urticaria 01/2022
1	Neurogenic Inflammation 12/2021
1	COVID-19 07/2021
1	Headache (Headaches) 01/2021
1	Chronic Pain 01/2021
1	Back Pain (Backache) 01/2021
1	Opioid-Related Disorders (Opiate Addiction) 01/2021
1	Erythema 01/2021
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021
1	Nasopharyngitis 01/2021
1	Rhinitis 01/2021
1	Hyperplasia 01/2021
1	Exanthema (Rash) 10/2020
1	Infections 01/2020
1	Lung Injury 01/2020
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Bronchiectasis 01/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Atopic Dermatitis (Atopic Eczema) 11/2019

Drug/Important Bio-Agent (IBA)

50	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2024 - 04/2012
11	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2024 - 05/2017
9	CytokinesIBA 05/2024 - 07/2012
9	dupilumabIBA 05/2024 - 09/2019
7	Cyclooxygenase 1IBA 01/2023 - 07/2016
5	Immunoglobulin E (IgE)IBA 01/2024 - 07/2014
5	Dinoprostone (PGE2)FDA Link 01/2023 - 07/2012
5	EnzymesIBA 01/2021 - 01/2010
4	Biomarkers (Surrogate Marker)IBA 01/2024 - 07/2017
4	Interleukin-13IBA 01/2024 - 11/2019
4	LeukotrienesIBA 01/2023 - 10/2013
4	ProstaglandinsIBA 01/2019 - 01/2010
3	mepolizumabIBA 01/2024 - 01/2021
3	Monoclonal AntibodiesIBA 01/2024 - 11/2019
3	Interleukin-5 (Interleukin 5)IBA 01/2024 - 01/2021
3	Opioid Analgesics (Opioids)IBA 11/2023 - 01/2021
3	RNA (Ribonucleic Acid)IBA 10/2023 - 01/2021
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 11/2016
3	Leukotriene E4IBA 01/2019 - 12/2013
3	Leukotriene C4IBA 10/2015 - 12/2013
3	Prostaglandins EIBA 06/2014 - 01/2010
2	Omalizumab (Xolair)FDA Link 01/2024 - 01/2024
2	Interleukin-33IBA 12/2023 - 10/2015
2	InterleukinsIBA 12/2023 - 11/2019
2	Small Cytoplasmic RNAIBA 10/2023 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 10/2015
2	Thromboxane Receptors (Thromboxane Receptor)IBA 06/2015 - 07/2012
2	AllergensIBA 06/2015 - 01/2010
1	Interleukin-6 (Interleukin 6)IBA 05/2024
1	AntigensIBA 04/2024
1	ChemokinesIBA 01/2024
1	Liraglutide FDA Link 12/2023
1	Analgesics (Analgesic Drugs)IBA 11/2023
1	Mechanistic Target of Rapamycin Complex 1IBA 10/2023
1	tezepelumabIBA 01/2023
1	Insulin ReceptorIBA 01/2023
1	Bronchodilator Agents (Bronchodilators)IBA 01/2023
1	anti-IgE antibodiesIBA 01/2023
1	cysteinyl-leukotrieneIBA 01/2023
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2023
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2022
1	Antitussive Agents (Antitussives)FDA Link 05/2022
1	Ion Channels (Ion Channel)IBA 12/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	Interleukin-4 (Interleukin 4)IBA 01/2021
1	InterferonsIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020

Therapy/Procedure

9	Therapeutics 05/2022 - 07/2012
2	Biological Therapy 01/2024 - 01/2020
2	Drug Therapy (Chemotherapy) 05/2022 - 09/2008
1	Arthroplasty 01/2023